Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

As conferences expand and money esclates in college football, is there a saturation point where fans say enough is enough? Is ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Meet Emanuel Colombini of Eccentrica Cars, whose Lamborghini Diablo restomod is an analogue supercar for the modern age ...

The Adelaide mom is met with sympathy, her husband with praise and both of them cop opinions that belong back in 1963. She’s ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

There had been a fleeting window of sympathy, and then the story flipped. Israel’s military steps became the headline—its ...